CytomX Therapeutics (FRA:6C1) Cyclically Adjusted PB Ratio: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6C1 CytomX Therapeutics Inc FRA:6C1
37 GF Score
Price €2.82
GF Value €0.23
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


CytomX Therapeutics  (FRA:6C1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CytomX Therapeutics Cyclically Adjusted PB Ratio Related Terms


CytomX Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Cyclically Adjusted PB Ratio Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.76 3.18

CytomX Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 2.20 3.18 3.64 0.00

FRA:6C1 vs BBOT, OMER, STTK: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:6C1
37GF Score
CytomX Therapeutics Inc FRA:6C1
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CytomX Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, CytomX Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.198/333.9520*333.9520
=1.198

Current CPI (Jun. 2026) = 333.9520.

CytomX Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.189 241.428 3.028
201612 2.039 241.432 2.820
201703 1.879 243.801 2.574
201706 1.262 244.955 1.721
201709 1.029 246.819 1.392
201712 1.535 246.524 2.079
201803 1.035 249.554 1.385
201806 0.903 251.989 1.197
201809 3.003 252.439 3.973
201812 2.552 251.233 3.392
201903 2.402 254.202 3.156
201906 1.978 256.143 2.579
201909 1.641 256.759 2.134
201912 1.011 256.974 1.314
202003 1.375 258.115 1.779
202006 1.131 257.797 1.465
202009 0.883 260.280 1.133
202012 -0.132 260.474 -0.169
202103 1.887 264.877 2.379
202106 1.668 271.696 2.050
202109 1.455 274.310 1.771
202112 -0.006 278.802 -0.007
202203 0.947 287.504 1.100
202206 0.701 296.311 0.790
202209 0.436 296.808 0.491
202212 -1.222 296.797 -1.375
202303 -1.220 301.836 -1.350
202306 -1.175 305.109 -1.286
202309 -0.718 307.789 -0.779
202312 -0.646 306.746 -0.703
202403 -0.428 312.332 -0.458
202406 -0.371 314.175 -0.394
202409 -0.270 315.301 -0.286
202412 -0.005 315.605 -0.005
202503 0.287 319.799 0.300
202506 0.630 322.561 0.652
202509 0.554 324.800 0.570
202512 0.497 324.054 0.512
202603 1.271 330.213 1.285
202606 1.198 333.952 1.198

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is CytomX Therapeutics (FRA:6C1) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of €2.82 is trading 1127.8% above its estimated GF Value™ of €0.23. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:6C1:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €0.23 vs. price of €2.82 (1127.8% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the FRA:6C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytomX Therapeutics Business Description

Other Exchanges CTMX:USA6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
37GF Score

Get the complete analysis for FRA:6C1

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.82
Price
€0.23
GF Value